Bupivacaine hydrochlo

DLA Troop Support Medical Supply Chain seeks quotes for two vials of Bupivacaine Hydrochloride Injection USP, 0.5%, 50 mL (NSN 6505-00-138-7347) under RFQ SPE2DP27T0203, issued by DLA office SPE2DP, with quotes due November 4, 2026 through DIBBS. The Set Aside line reads "No Set-Aside Used," and the solicitation is a Fast Auto Evaluation request for quotation.

The item requires delivery within 5 days on FOB Destination terms with inspection at destination. Per the attached RFQ summary, delivery is to US Army SSA Powidz AB in Poland, with an original required delivery date of October 30, 2026. The specified product is Pfizer Inc.'s Bupivacaine Hydrochloride Injection USP, 0.5%, 50 mL vial (NDC 00409-1163-18). The summary also states that quoters are encouraged to submit quantity ranges because of demand volatility.

Compliance requirements include Buy American and Balance of Payments Program provisions under DFARS 252.225-7001 for quotes above the micro-purchase threshold, hazardous material provisions, packaging and marking per Medical Marking Standard No. 1, cybersecurity safeguarding, export-controlled item provisions, and compliance for covered defense telecommunications equipment. Additive manufacturing items are excluded unless specifically authorized. The contract is fixed-price, with invoicing through WAWF. Fast Pay procedures apply if the final award is at or below the simplified acquisition threshold under FAR 13.402(a), and micro-purchase quotes may be awarded before the return date.

Per the attached RFQ summary, this NSN has been procured multiple times between February 2025 and August 2026 from two vendors, identified as CAGE codes 3W8H0 and 00E55, at unit costs of approximately $3.24 to $11.27. The source states no evaluation criteria.